NCT05018403View on ClinicalTrials.gov

First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2022

Conditions
Healthy
Interventions
DRUG

Intravenous AON-D21

AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.

DRUG

Intravenous placebo

Isotonic glucose solution identical in appearance to AON-D21.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors
All Listed Sponsors
lead

Aptarion Biotech AG

INDUSTRY